Research programme: infectious disease therapeutics - Synthetic Biologics/Intrexon Corporation

Drug Profile

Research programme: infectious disease therapeutics - Synthetic Biologics/Intrexon Corporation

Alternative Names: anti-Acinetobacter mAbs - Synthetic Biologics/Intrexon; anti-pertussis mAbs - Synthetic Biologics/Intrexon; hu1B7; hu1B7-YTE; Pertussis (whooping cough) monoclonal antibody - Synthetic Biologics; SYN-001; SYN-005; SYN-007

Latest Information Update: 04 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intrexon Corporation; Synthetic Biologics
  • Developer Intrexon Corporation; Synthetic Biologics; University of Texas at Austin
  • Class Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pertussis
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Pertussis; Phenylketonuria
  • Research Inflammatory bowel diseases
  • No development reported Acinetobacter infections; Infections

Most Recent Events

  • 21 Apr 2018 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Pertussis presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases
  • 04 May 2017 Preclinical data in Pertussis released by Synthetic Biologics
  • 19 Apr 2017 Pharmacodynamics data from a preclinical study in Pertussis released by Synthetic Biologics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top